Gain Therapeutics (GANX) Depreciation & Amortization (CF) (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Depreciation & Amortization (CF) of $21303.0 for Q1 2026, up 3.11% year-over-year from $20660.0 in Q1 2025, and down 24.57% quarter-over-quarter from $28241.0 in Q4 2025.
Gain Therapeutics (GANX) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Gain Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $21303.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 3.11% year-over-year to $21303.0; the TTM figure through Mar 2026 stood at $94689.0 (up 12.45% YoY), while the FY2025 annual figure was $94046.0, up 11.86% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $21303.0, down from $28241.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $28241.0 in Q4 2025, with the low at $8209.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $20593.0 (2024), against an average of $20421.6.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) jumped 827.76% in 2022, then retreated 9.67% in 2024.
- Gain Therapeutics' Depreciation & Amortization (CF) stood at $18110.0 in 2022, then surged by 30.25% to $23589.0 in 2023, then dropped by 9.67% to $21307.0 in 2024, then surged by 32.54% to $28241.0 in 2025, then dropped by 24.57% to $21303.0 in 2026.
- Business Quant data shows GANX's Depreciation & Amortization (CF) at $21303.0 in Q1 2026, $28241.0 in Q4 2025, and $22817.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | 27,170.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27,170.00 |
| Jun 30, 2026 | 27,170.00 |
| Mar 31, 2026 | 21,303.00 |
| Mar 31, 2026 | 21,303.00 |
| Dec 31, 2025 | 28,241.00 |
| Dec 31, 2025 | 28,241.00 |
| Sep 30, 2025 | 22,817.00 |
| Sep 30, 2025 | 22,817.00 |
| Jun 30, 2025 | 22,328.00 |
| Jun 30, 2025 | 22,328.00 |
| Mar 31, 2025 | 20,660.00 |
| Mar 31, 2025 | 20,660.00 |
| Dec 31, 2024 | 21,307.00 |
| Dec 31, 2024 | 21,307.00 |
| Sep 30, 2024 | 21,643.00 |
| Sep 30, 2024 | 21,643.00 |
| Jun 30, 2024 | 20,593.00 |
| Jun 30, 2024 | 20,593.00 |
| Mar 31, 2024 | 20,528.00 |
| Mar 31, 2024 | 20,528.00 |